| Company Name: |
T&W GROUP |
| Tel: |
021-61551611 13296011611 |
| Email: |
contact@trustwe.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
inquiry@bocsci.com |
Uridine, 4',5'-didehydro-2',5'-dideoxy- manufacturers
|
| | Uridine, 4',5'-didehydro-2',5'-dideoxy- Basic information |
| Product Name: | Uridine, 4',5'-didehydro-2',5'-dideoxy- | | Synonyms: | Uridine, 4',5'-didehydro-2',5'-dideoxy-;4',5'-Didehydro-2',5'-dideoxyuridine;4’,5’-Didehydro-2’,5’-dideoxyuridine;1-(2,5-dideoxy-β-D-glycero-pent-4-enofuranosyl)uracil | | CAS: | 58096-66-5 | | MF: | C9H10N2O4 | | MW: | 210.19 | | EINECS: | | | Product Categories: | | | Mol File: | 58096-66-5.mol |  |
| | Uridine, 4',5'-didehydro-2',5'-dideoxy- Chemical Properties |
| density | 1.47±0.1 g/cm3(Predicted) | | pka | 9.34±0.10(Predicted) |
| | Uridine, 4',5'-didehydro-2',5'-dideoxy- Usage And Synthesis |
| Uses | 4′,5′-Didehydro-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | Uridine, 4',5'-didehydro-2',5'-dideoxy- Preparation Products And Raw materials |
|